Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854737 · ClinicalTrials.gov registry record · Phase 2
Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
A Phase 2 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00854737 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 90 participants.
The verdict
NCT00854737, a Phase 2 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.
Interventions
- DRUG placebo
- DIETARY_SUPPLEMENT cytidine
- DIETARY_SUPPLEMENT omega-3 fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854737
The ClinicalTrials.gov registry entry for NCT00854737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00854737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00854737 about?
NCT00854737 is a clinical study titled "Cytidine and Omega-3 Fatty Acids in Bipolar Disorder". The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 r...
What is the current status of trial NCT00854737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2004-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00854737?
The interventions under investigation include: placebo (DRUG), cytidine (DIETARY_SUPPLEMENT), omega-3 fatty acids (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00854737?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.